tirzepatide shortage fda update says the weight-loss drug is over FDA Affirms Decision on Tirzepatide

All of the outcomes assessed were prespecified as exploratory outcomes, with the exception of estimated BV and PV, which were post hoc and not prespecified

Consider tracking additional metrics including waist circumference, body composition if available, and how clothing fits, as these may reveal fat loss that is not immediately apparent on the scale

Evaluation exists precisely to determine that

Consequently, researchers use it to examine incretin synergy mechanisms precisely

A safe prescribing decision also considers: eligibility and NHS pathway availability comorbidities and concurrent medicines tolerability and dose escalation patient preference and expectations capacity for follow-up and monitoring The difference between semaglutide and tirzepatide should therefore be framed as a clinical comparison, not a direct consumer recommendation